CLINICAL REPORT

Evaluation for Bleeding Disorders in Suspected Child Abuse

abstract

Bruising or bleeding in a child can raise the concern for child abuse. Assessing whether the findings are the result of trauma and/or whether the child has a bleeding disorder is critical. Many bleeding disorders are rare, and not every child with bruising/bleeding concerning for abuse requires an evaluation for bleeding disorders. In some instances, however, bleeding disorders can present in a manner similar to child abuse. The history and clinical evaluation can be used to determine the necessity of an evaluation for a possible bleeding disorder, and prevalence and known clinical presentations of individual bleeding disorders can be used to guide the extent of the laboratory testing. This clinical report provides guidance to pediatricians and other clinicians regarding the evaluation for bleeding disorders when child abuse is suspected.

INTRODUCTION

Children often present for medical care with bleeding or bruising that can raise a concern for child abuse. Most commonly, this occurs with cutaneous bruises and intracranial hemorrhage (ICH), but other presentations, such as hematemesis, hematochezia, and oronasal bleeding can be caused by child abuse and/or bleeding disorders. When bleeding or bruising is suspicious for child abuse, careful consideration of medical and other causes is warranted. The inappropriate diagnosis of child abuse could occur, potentially resulting in the removal of a child from a home and/or the potential prosecution of an innocent person. Conversely, attributing an abusive injury to medical causes or accidental injury puts a child at risk for future abuse and possible death. Laboratory evaluations should be conducted with the understanding that the presence of a bleeding disorder does not rule out abuse as the etiology for bruising or bleeding. Similarly, the presence of a history of trauma (accidental or nonaccidental) does not exclude the presence of a bleeding disorder or other medical condition. This clinical report provides guidance to pediatricians and other clinicians regarding the evaluation for bleeding disorders when child abuse is suspected (Fig 1).
ASSESSING THE NEED FOR A LABORATORY EVALUATION FOR BLEEDING DISORDERS

The age and developmental capabilities of the child, history of trauma, the location and pattern of bruising, and, in the case of ICH, findings on neuroimaging should be considered when assessing children with bruising/bleeding for possible abuse.12–18 Additionally, a medical history of symptoms suggestive of a bleeding disorder, such as significant bleeding after a circumcision or other surgery, epistaxis, bleeding from the umbilical stump, or excessive bleeding after dental procedures, increases the possibility of a bleeding disorder. Family history of a specific bleeding disorder or ethnicity of a population with higher rates of a certain bleeding disorder (eg, Amish) might necessitate testing for that condition. The child’s medications should be documented, because certain drugs can affect the results of some tests that might be used to detect bleeding disorders, such as the platelet function analyzer (PFA-100; Siemens Healthcare Diagnostics, Tarrytown, NY) and platelet aggregation testing. Caregivers might state that their child “bruises easily.” These statements are difficult to assess during an evaluation for possible abuse, as they can be a sign of a bleeding disorder, a reflection of the child’s (fair) skin tone, or a fabrication to mask abuse. Children who are verbal and capable of providing a history should be interviewed away from potential offending caregivers, if possible. A thorough physical examination should include an evaluation of areas of bruising that have higher specificity for abuse,14 such as the buttocks, ears, and genitals.

Any bleeding disorder can cause cutaneous bruising, and sometimes this bruising can be mild, can appear in locations that are considered suspicious for abuse,19 and can appear at any age. Given the extreme rarity of some bleeding disorders, it is not reasonable to perform extensive laboratory testing for bleeding disorders in every child. In some cases, the constellation of findings, taken in conjunction with the clinical history and physical examination, can be so strongly consistent with an abusive injury that further laboratory investigation for medical conditions is not warranted. For instance, a child with a patterned slap mark who describes being hit with an open hand does not require a laboratory evaluation for a bleeding disorder.

In addition to bleeding disorders, the possibility of other medical causes of easy bruising or bleeding, such as Ehlers-Danlos syndrome, scurvy, cancer and other infiltrative disorders, glutaric aciduria, and arteriovenous malformations, should be assessed, as should a history of use of any medications or alternative therapies that may increase bleeding/bruising.

FIGURE 1
Recommended pathway for evaluation of possible bleeding disorders when child abuse is suspected.

VWF, von Willebrand factor.
bleeding/bruising are beyond the scope of this report and can be found elsewhere. Results of the history, review of systems, physical examination, and, in the case of ICH, neuroimaging are generally adequate to exclude these conditions. When there are concerns that a medical condition might be the cause of bruising or bleeding, the evaluation for the conditions in question should occur simultaneously with the evaluation for abuse.

### Bruising

In the absence of independently witnessed accidental trauma or a known medical cause, any bruising in a non-mobile child is highly concerning for abuse and necessitates an evaluation for child abuse. Additionally, bruising in a young infant could also be the first presentation of a bleeding disorder. As such, a simultaneous evaluation for bleeding disorders is recommended in these cases. In mobile children, the locations and patterns of the bruising can be used to assess for the possibility of abuse (Table 1).

<table>
<thead>
<tr>
<th>Location</th>
<th>Pattern</th>
<th>Characteristic of Bruises</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forehead</td>
<td>Slap or hand marks</td>
<td>Large cumulative size of bruising</td>
</tr>
<tr>
<td>Under chin</td>
<td>Object marks</td>
<td>Multiple bruises of uniform shape</td>
</tr>
<tr>
<td>Elbows</td>
<td>Bite marks</td>
<td>Multiple bruises in clusters</td>
</tr>
<tr>
<td>Lower arms</td>
<td>Slap or hand marks</td>
<td>Large cumulative size of bruising</td>
</tr>
<tr>
<td>Hips</td>
<td>Object marks</td>
<td>Slap or hand marks</td>
</tr>
<tr>
<td>Shins</td>
<td>Bite marks</td>
<td>Bite marks</td>
</tr>
<tr>
<td>Ankles</td>
<td>Slap or hand marks</td>
<td>Slap or hand marks</td>
</tr>
</tbody>
</table>

In cases of bruising, the assessment of the need for an evaluation for bleeding disorders should focus on the following:

- the specific history offered to explain the bruising;
- the nature and location of bruising;
- mobility and developmental status of the child.

The following factors generally exclude the need for an evaluation for a bleeding disorder:

- the caregivers’ description of trauma sufficiently explains the bruising;
- the child or an independent witness is able to provide a history of abuse or nonabusive trauma that explains the bruising; or
- abusive object or hand-patterned bruising is present.

The injury history offered by caregivers might be purposefully misleading if the caregivers have caused the bruising by abusive means.

In nonmobile infants, bleeding disorders can present with bruising or petechiae in sites of normal handling or pressure. Examples of this include the following:

- petechiae at clothing line pressure sites;
- bruising at sites of object pressure, such as in the pattern and location of infant seat fasteners; and
- excessive diffuse bleeding if the child has a severe bleeding disorder.

Absence of these examples does not rule out a bleeding disorder; however, their presence might increase the probability of a bleeding disorder.

### ICH

Excepting obvious known trauma, ICH in a nonmobile child is highly concerning for child abuse. Children can suffer ICH, such as a small subdural or an epidural hematoma underlying a site of impact, from a short fall; however, short falls rarely result in significant brain injury. Birth trauma and some medical conditions can also result in ICH in infants. Consultation with a child abuse pediatrician should be considered in complex or concerning cases.

No studies have systematically compared the presentation, clinical findings, patterns of ICH, or presence of retinal hemorrhages found in children with bleeding disorders with those found in children in whom abusive head trauma is diagnosed. However, bleeding disorders can cause ICH in any part of the cranial contents, and up to 12% of children and young adults with bleeding disorders have had ICH at some time. Children with ICH concerning for abuse require an evaluation for bleeding disorders. Exceptions to required evaluation can include the following:

- Independently witnessed or verifiable trauma (abusive or nonabusive);
- Other findings consistent with abuse, such as fractures, burns, or internal abdominal trauma.

### Other Bleeding Symptoms

Children with conditions such as hematemesis, hematochezia, or oronasal bleeding as presenting symptoms should be evaluated on a case-by-case basis for possible abuse, particularly child abuse in a medical setting. Medical conditions and/or child abuse can cause these findings.

### BLEEDING DISORDERS AND EXTENT OF EVALUATION

Bleeding disorders that can produce patterns of bruising or bleeding that mimic abuse include coagulation factor deficiencies/abnormalities, fibrinolytic
defects, defects of fibrinogen, and platelet disorders. Table 2 contains a listing of the most common bleeding disorders in children and characteristics of potential testing strategies for each disorder. Most factor deficiencies can be detected by the prothrombin time (PT) and activated partial thromboplastin time (aPTT); however, von Willebrand disease (VWD) and factor XIII deficiency are not reliably detected by these screening tests. Additionally, mild deficiencies in factor VIII or factor IX (mild hemophilia) might not cause abnormalities in the aPTT but might still result in significant bleeding, including ICH, particularly after mild trauma. Fibrinolytic defects can cause significant bleeding/bruising but are extremely rare and require specific testing. Defects of fibrinogen are also rare and can be detected by the fibrinogen concentration and thrombin time.

The prevalence of mild platelet disorders is unknown, and testing for mild platelet disorders is challenging. The most common clinical presentations include bruising and mucocutaneous bleeding. The prevalence of ICH in mild platelet disorders is unknown but is likely to be low. Platelet aggregation testing, best performed by a pediatric hematologist, requires a relatively large volume of blood, and interpretation of the test result requires a specialist. A PFA-100 can screen for many platelet function disorders, including more severe types, such as Bernard Soulier syndrome and Glanzmann thrombasthenia, as well as many types of VWD. However, the PFA-100 is not an effective screen for some types of VWD and milder platelet abnormalities. Individual patient characteristics, such as hematocrit, platelet count, pregnancy, age, multisystem trauma, sepsis, and medications, can affect the results of the PFA-100. Accurate diagnosis often requires additional testing, such as specific von Willebrand testing or platelet aggregation; therefore, many centers have decreased or ceased use of the PFA-100. Assessment of the results of a PFA-100 and the need for further testing are best accomplished in consultation with a pediatric hematologist.

**Vitamin K Deficiency**

Vitamin K deficiency in infants can result in bleeding in the skin or from mucosal surfaces from circumcision, generalized ecchymoses, large intramuscular hemorrhages, or ICH. Because of the widespread provision of vitamin K at birth, vitamin K deficiency bleeding (VKDB) is rare; however, not all states require vitamin K to be administered at birth, and some medical conditions predispose to VKDB. In VKDB, there is a prolonged PT and possibly aPTT for age. In patients who have already received vitamin K, fresh-frozen plasma, or specific factor replacement as treatment, measurement of proteins induced by vitamin K absence can confirm the diagnosis.

**Coagulation Tests in Cases of Bruising**

The initial screening panel in a patient who presents with bruising evaluates for conditions with a known prevalence more common than 1 per 500,000 people, including idiopathic thrombocytopenic purpura, all factor deficiencies (except factor XIII deficiency), and VWD (Fig 1). It does not evaluate for extremely rare conditions, including factor XIII deficiency, defects of fibrinogen, and fibrinolytic defects. This strategy also does not screen for extremely rare platelet disorders, such as Glanzmann thrombasthenia, and more common but relatively more difficult to detect platelet disorders, such as platelet storage pool disorders. If test results are abnormal or expanded/detailed testing is necessary or preferred, consultation with a pediatric hematologist is recommended.

In many circumstances, children with bruising that is suspicious for abuse may be removed from a potentially dangerous setting where the abuse likely occurred. A thorough physical examination performed in the weeks after removal that reveals minimal bruising and/or bruising only in locations of common accidental bruises is supportive of abuse as the cause of the original suspicious bruising. Each case must be evaluated individually, however, considering the totality of findings, and with the understanding that the need for safety must be balanced with the emotional trauma of removing a child from his or her home. Bleeding disorders are generally permanent conditions that do not result in abatement after a change in caregivers. One exception to this is immune thrombocytopenia (ITP), which is a transient, often self-resolving bleeding disorder. Screening for ITP (platelet count) is necessary at the time of presentation with bruises.

**Determining the Need for a Test: The Medical Probability**

Specific data regarding the prevalence of bleeding disorders in the population of children with ICH or subdural hematoma is not available. However, there are data regarding the probability of specific bleeding disorders to cause ICH. If the prevalence of a condition and the frequency of a particular presentation of that condition are known, a physician can construct the probability of that specific condition (bleeding disorder) resulting in the specific presentation (ICH). The presence of “classic” bleeding symptoms, such as bleeding after circumcision,
<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Inheritance</th>
<th>Screening Tests</th>
<th>Sn and Sp, %</th>
<th>PPV and NPV, %</th>
<th>Confirmatory Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor abnormalities/deficiencies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VWD type 1</td>
<td>1/1000</td>
<td>AD</td>
<td>PFA-100</td>
<td>Sn = 79–98®</td>
<td>PPV = 93.3</td>
<td>WA® activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sp = 88–96®</td>
<td>NPV = 98.2</td>
<td>WA® activity</td>
</tr>
<tr>
<td>VWD type 2A</td>
<td>Uncommon</td>
<td>AD or AR</td>
<td>PFA-100</td>
<td>Sn = 94–100®</td>
<td>PPV = 93.3</td>
<td>WA® activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sp = 88–96®</td>
<td>NPV = 98.2</td>
<td>WA® activity</td>
</tr>
<tr>
<td>VWD type 2B</td>
<td>Uncommon</td>
<td>AD</td>
<td>PFA-100</td>
<td>Sn = 93–98®</td>
<td>PPV = 93.3</td>
<td>WA® activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sp = 88–96®</td>
<td>NPV = 98.2</td>
<td>WA® activity</td>
</tr>
<tr>
<td>VWD type 2M</td>
<td>Uncommon</td>
<td>AD or AR</td>
<td>PFA-100</td>
<td>Sn = 94–97®</td>
<td>PPV = 93.3</td>
<td>WA® activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sp = 88–96®</td>
<td>NPV = 98.2</td>
<td>WA® activity</td>
</tr>
<tr>
<td>VWD type 2N</td>
<td>Uncommon</td>
<td>AR, or compound heterozygote</td>
<td>aPTT</td>
<td>NA</td>
<td>NA</td>
<td>VWF-Factor VIII binding assay</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PFA-100</td>
<td>Sn = 94–100®</td>
<td>PPV = 93.3</td>
<td>WA® activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sp = 88–96®</td>
<td>NPV = 98.2</td>
<td>WA® activity</td>
</tr>
<tr>
<td>Factor II deficiency (prothrombin)</td>
<td>26 reported cases, estimated 1/1–2 million</td>
<td>AR</td>
<td>aPTT, PT (may be normal)</td>
<td>Sn = variable</td>
<td>NA</td>
<td>Factor II activity ± antigen levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factor V deficiency</td>
<td>1/1 million</td>
<td>AR</td>
<td>aPTT, PT</td>
<td>Sn = variable</td>
<td>NA</td>
<td>Factor V activity</td>
</tr>
<tr>
<td>Combined Factor V/Factor VIII deficiency</td>
<td>1/1 million</td>
<td>AR</td>
<td>aPTT&gt;PT</td>
<td>Sn = variable</td>
<td>NA</td>
<td>Factor V and Factor VIII activities</td>
</tr>
<tr>
<td>Factor VII deficiency</td>
<td>1/30 000–50 000</td>
<td>AR</td>
<td>PT</td>
<td>Sn = variable</td>
<td>NA</td>
<td>Factor VII activity</td>
</tr>
<tr>
<td>Factor IX deficiency</td>
<td>1/20 000 male births</td>
<td>X-linked</td>
<td>aPTT</td>
<td>Sn = variable</td>
<td>NA</td>
<td>Factor IX activity</td>
</tr>
<tr>
<td>Factor X deficiency</td>
<td>1/1 million</td>
<td>AR</td>
<td>aPTT, PT, RVV</td>
<td>Sn = variable</td>
<td>NA</td>
<td>Factor X activity</td>
</tr>
<tr>
<td>Factor XI deficiency</td>
<td>1/100 000</td>
<td>AR</td>
<td>aPTT</td>
<td>Sn = variable</td>
<td>NA</td>
<td>Factor XI activity</td>
</tr>
<tr>
<td>Factor XIII deficiency</td>
<td>1/2–5 million</td>
<td>AR</td>
<td>Clot solubility</td>
<td>Sn = variable</td>
<td>NA</td>
<td>Factor XIII activity</td>
</tr>
<tr>
<td>Fibrinolytic defects</td>
<td>~40 reported cases</td>
<td>AR</td>
<td>Euglobin lysis test</td>
<td>Sn = variable</td>
<td>NA</td>
<td>α-2-antiplasmin activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Defects of fibrinogen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abl fibrinogenemia</td>
<td>1/500 000</td>
<td>AR</td>
<td>PT, aPTT</td>
<td>Sn = high</td>
<td>NA</td>
<td>Fibrinogen level</td>
</tr>
<tr>
<td>Hypofibrinogenemia</td>
<td>Less than ab fibrinogenemia</td>
<td></td>
<td>PT, aPTT</td>
<td>Sn = variable</td>
<td>NA</td>
<td>Thrombin time, fibrinogen activity</td>
</tr>
<tr>
<td>Dysfibrinogenemia</td>
<td>1/million</td>
<td>AR</td>
<td>Thrombin time, fibrinogen level</td>
<td>Sn = variable</td>
<td>NA</td>
<td>Thrombin time, fibrinogen antigen and activity level comparison, reptilase time</td>
</tr>
<tr>
<td>Platelet disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITP</td>
<td>Age-related</td>
<td>NA</td>
<td>CBC</td>
<td>Sn = high</td>
<td>NA</td>
<td>Antiplatelet Ab (rarely needed)</td>
</tr>
<tr>
<td>Glanzmann thrombasthenia</td>
<td>Very rare</td>
<td>AR</td>
<td>PFA-100</td>
<td>Sn = 97–100</td>
<td>NA</td>
<td>Platelet aggregation testing Flow cytometry</td>
</tr>
</tbody>
</table>
TABLE 2 Continued

<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Inheritance</th>
<th>Screening Tests</th>
<th>Confirmation Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernard Soulier syndrome</td>
<td>Rare</td>
<td>AR</td>
<td>PFA-100</td>
<td>NA</td>
</tr>
<tr>
<td>Platelet release/storage disorders</td>
<td>Unknown, more common than variable</td>
<td>PFA-100</td>
<td>Sn = 27–50</td>
<td>NA</td>
</tr>
<tr>
<td>Other platelet function disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values derived from data before 2008 National Institutes of Health Consensus guidelines. Sn and Sp using current diagnostic cutoffs unknown but would be expected to have higher Sp with lower Sn.

**Coagulation Tests in the Setting of ICH**

For bleeding disorders that cause ICH, the prevalence of the bleeding disorder and the prevalence of ICH in patients with each specific bleeding disorder can be used to construct the probability of the specific bleeding disorder to cause ICH (Table 3). Some probabilities are so low as to preclude calculation. Testing for these conditions is likely not useful. Mild hemophilia, which might be missed if only an aPTT test is ordered, can be detected by measuring specific levels of factor VIII and factor IX. Mild hemophilia can result in ICH, particularly after mild trauma, and because of the relatively high prevalence of the condition, the probability of mild factor VIII deficiency causing or contributing to ICH is 1 in 280,000 males. In populations with a high prevalence of factor XI deficiency, such as the Ashkenazi Jewish population, it might be reasonable to measure factor XI level.

Clinical and historical information can be used to determine the need for testing in children with isolated ICH concerning for abuse (Fig 1). The initial testing panel for ICH evaluates for conditions for which the probability for the condition resulting in ICH is greater than 1 per 5 million. The panel includes testing for most factor deficiencies and afibrinogenemia. This screening panel does not test for factor XIII deficiency, VWD, fibrinolytic defects, hypofibrinogenemia, and dysfibrinogenemia. These conditions either have not been associated with ICH or they are so rarely the cause of ICH that testing for the conditions is not reasonable. Additionally, the initial screening panel evaluates for disseminated intravascular coagulation (DIC). Because DIC can cause any type of bruising/bleeding, including ICH, the finding of DIC in the context of suspected child abuse could significantly change the clinical approach to a patient. In children with DIC and bleeding symptoms as the only finding concerning for abuse, consideration must be given to the multitude of primary causes of DIC, including trauma, sepsis, and primary bleeding disorders, among many others.

Many children with ICH suspicious for abuse, if they survive, are placed in safe settings after hospital discharge. In these cases, testing for bleeding disorders can be deferred to a later date, with the exception of ITP. If blood products have been given to the patient, as can happen in severe ICH, the definitive evaluation for bleeding disorders should be postponed until the transfused blood components are no longer in the patient’s system (Table 4). Assistance from a pediatric hematologist should be considered in addressing the possibility of factor deficiencies after a transfusion has occurred.

Many aspects of bleeding disorders are under investigation, and thus, changes in the understanding of the prevalence and severity of certain bleeding symptoms related to these disorders should be expected. For example, although hemophilia A and B are X-linked diseases and, therefore, typically thought to affect only male individuals, 25% to 50% of female carriers of hemophilia report excess bleeding; therefore, measurement of factor VIII and IX levels in female patients should be considered. In addition, the population prevalence and/or clinical effects of mild platelet function disorders continue to be studied. In a patient with mucocutaneous symptoms, particularly if petechiae are
present, platelet aggregation testing should be considered. Finally, because von Willebrand factor is an acute phase reactant, its levels can vary in response to clinical status, resulting in falsely elevated results. Many times, testing must be repeated up to 3 times to ensure reliable results. If significant concern for VWD exists, consultation with a pediatric hematologist is suggested.

When Testing Indicates a Possible Bleeding Disorder in the Context of an Abuse Evaluation

Positive laboratory test results require further evaluation for the possibility of false-positive results and/or the necessity for further testing. Prolongation of the PT and aPTT because of parenchymal damage has been noted in abusive head trauma and should not automatically be interpreted as evidence of a primary bleeding disorder. Additionally, consideration must be given to the likelihood of a preexisting bleeding disorder as the primary cause of a child’s bleeding/bruising. For example, given the relatively high prevalence of VWD, it is inevitable that some children with VWD will be abused and present with bleeding/bruising symptoms. Determining the causative factor in these situations is challenging. Bruising is a common finding in VWD. If a child has test results consistent with VWD and bruising concerning for abuse, a short-term change in home setting may be considered, understanding the cautions needed when using this approach. Only a few case reports have attributed ICH to VWD. Most reported ICH in children with VWD would not be confused with typical abusive ICH. Given the rarity of ICH in VWD, particularly spontaneous ICH, testing consistent with VWD does not mean that ICH is definitively attributable to VWD, and abuse must still be considered.

Interpretation of Tests

It should be noted that the aPTT can be falsely prolonged in certain circumstances, such as in the presence of a lupus anticoagulant, or can be prolonged and might not indicate a true bleeding disorder, such as in factor XII deficiency or other contact factor deficiencies. In addition, patients who experience a traumatic brain injury often have a transient coagulopathy that does not reflect an underlying congenital disorder. Coagulation tests are very sensitive to specimen handling and should be performed in laboratories experienced with these assays. Inappropriate handling commonly leads to false-positive results.

CONCLUSIONS

Children who present with bleeding and bruising symptoms that are concerning for abuse require careful evaluation for the potential of bleeding disorders as a cause. No single panel of tests rules out every possible bleeding disorder. Given the rarity of most bleeding disorders and the possible presence of specific clinical factors that decrease the likelihood of a bleeding disorder causing a child’s findings, in many situations, extensive laboratory evaluation is not necessary.
necessary. If a laboratory evaluation is conducted, tests should be chosen on the basis of the prevalence of the condition, patient and family history, ease of testing, blood volume required for testing, and, in the case of ICH, probability of a bleeding disorder causing ICH. Further consultation with a pediatric hematologist is recommended if specific, expanded testing is necessary, if preliminary testing suggests the presence of a bleeding disorder, if testing to rule out a specific bleeding disorder is needed, or if testing for very rare conditions is preferred.

**GUIDANCE FOR PEDIATRICIANS**

In children who have bruising or bleeding that is suspicious for abuse,

1. Complete medical, trauma, and family histories and a thorough physical examination are critical tools in evaluating for the possibility of abuse or medical conditions that predispose to bleeding/bruising.

2. In each case, careful consideration of the possibility of a medical condition causing the bleeding/bruising is essential. Specific elements of the history and characteristics of the bleeding/bruising can be used to determine the need for a laboratory evaluation for bleeding disorders.

3. If the evaluation indicates a need for laboratory testing for bleeding disorders, initial testing is focused on the prevalence of the condition and potential of each specific condition to cause the specific findings in a given child (Fig 1).

4. Laboratory testing suggestive or indicating the presence of a bleeding disorder does not eliminate abuse from consideration. In children with bruising and laboratory testing suggestive of a bleeding disorder, a follow-up evaluation after a change in home setting can provide valuable information regarding the likelihood of a bleeding disorder causing the concerning findings.

5. Children with ICH often receive blood product transfusions. It is suggested that screening for bleeding disorders in these patients be delayed until elimination of the transfused blood clotting elements.

6. The discovery of new information regarding condition prevalence, laboratory testing, and clinical presentations of bleeding disorders is to be expected. Close collaboration with a pediatric hematologist is necessary to ensure the most current evaluation and testing methods.

**REFERENCES**


Evaluation for Bleeding Disorders in Suspected Child Abuse
James D. Anderst, Shannon L. Carpenter, Thomas C. Abshire and the SECTION ON HEMATOLOGY/ONCOLOGY and COMMITTEE ON CHILD ABUSE AND NEGLECT

Pediatrics 2013;131:e1314
DOI: 10.1542/peds.2013-0195 originally published online March 25, 2013;

Updated Information & Services including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/131/4/e1314

References This article cites 30 articles, 11 of which you can access for free at:
http://pediatrics.aappublications.org/content/131/4/e1314.full#ref-list-1

Subspecialty Collections This article, along with others on similar topics, appears in the following collection(s):
Current Policy
http://classic.pediatrics.aappublications.org/cgi/collection/current_policy
Committee on Child Abuse and Neglect
http://classic.pediatrics.aappublications.org/cgi/collection/committee_on_child_abuse_and_neglect
Section on Hematology/Oncology
http://classic.pediatrics.aappublications.org/cgi/collection/section_on_hematology_oncology
Child Abuse and Neglect
http://classic.pediatrics.aappublications.org/cgi/collection/child_abuse_neglect_sub

Permissions & Licensing Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
https://shop.aap.org/licensing-permissions/

Reprints Information about ordering reprints can be found online:
http://classic.pediatrics.aappublications.org/content/reprints
Evaluation for Bleeding Disorders in Suspected Child Abuse
James D. Anderst, Shannon L. Carpenter, Thomas C. Abshire and the SECTION ON HEMATOLOGY/ONCOLOGY and COMMITTEE ON CHILD ABUSE AND NEGLECT

Pediatrics 2013;131;e1314
DOI: 10.1542/peds.2013-0195 originally published online March 25, 2013;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/131/4/e1314

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2013 by the American Academy of Pediatrics. All rights reserved. Print ISSN: .